Your browser is no longer supported. Please, upgrade your browser.
EXEL Exelixis, Inc. daily Stock Chart
EXEL [NASD]
Exelixis, Inc.
Index- P/E26.76 EPS (ttm)0.93 Insider Own1.30% Shs Outstand305.39M Perf Week6.22%
Market Cap7.65B Forward P/E28.15 EPS next Y0.89 Insider Trans-30.02% Shs Float297.08M Perf Month7.83%
Income293.80M PEG0.58 EPS next Q0.12 Inst Own83.00% Short Float5.46% Perf Quarter38.40%
Sales979.20M P/S7.82 EPS this Y-53.80% Inst Trans3.93% Short Ratio4.78 Perf Half Y33.87%
Book/sh5.72 P/B4.36 EPS next Y99.10% ROA16.20% Target Price29.85 Perf Year19.27%
Cash/sh3.11 P/C8.02 EPS next 5Y46.00% ROE18.00% 52W Range13.67 - 27.80 Perf YTD41.54%
Dividend- P/FCF18.77 EPS past 5Y22.50% ROI17.30% 52W High-10.29% Beta1.47
Dividend %- Quick Ratio8.00 Sales past 5Y107.60% Gross Margin96.40% 52W Low82.44% ATR0.90
Employees617 Current Ratio8.10 Sales Q/Q5.30% Oper. Margin34.50% RSI (14)58.23 Volatility3.47% 4.08%
OptionableYes Debt/Eq0.00 EPS Q/Q-36.10% Profit Margin30.00% Rel Volume1.08 Prev Close24.18
ShortableYes LT Debt/Eq0.00 EarningsMay 05 AMC Payout0.00% Avg Volume3.39M Price24.94
Recom2.00 SMA207.13% SMA503.26% SMA20027.51% Volume3,660,289 Change3.14%
Mar-04-20Initiated Barclays Overweight $26
Jan-13-20Initiated SunTrust Buy $31
Nov-13-19Initiated BofA/Merrill Buy $22
Mar-18-19Upgrade Morgan Stanley Underweight → Equal-Weight
Sep-17-18Initiated Goldman Neutral $22
Sep-10-18Initiated Morgan Stanley Underweight $19
May-11-18Reiterated Needham Buy $33 → $30
Oct-17-17Reiterated RBC Capital Mkts Outperform $33 → $39
Oct-17-17Reiterated Needham Buy $30 → $33
Oct-16-17Reiterated SunTrust Buy $32 → $35
Sep-22-17Downgrade Leerink Partners Outperform → Mkt Perform
Sep-15-17Initiated RBC Capital Mkts Outperform $32
Sep-12-17Reiterated Needham Buy $28 → $30
Jul-14-17Initiated SunTrust Buy $33
Mar-31-17Initiated Needham Buy $28
Mar-16-17Initiated Oppenheimer Perform
Feb-28-17Downgrade Stifel Buy → Hold $21 → $22
Nov-03-16Initiated Deutsche Bank Buy $17
Oct-10-16Upgrade Piper Jaffray Neutral → Overweight
Sep-15-16Reiterated Stifel Buy $12 → $15
Jul-10-20 07:16AM  
05:51AM  
Jul-03-20 12:36PM  
Jun-30-20 08:00AM  
Jun-22-20 11:02PM  
Jun-18-20 04:05PM  
Jun-17-20 01:42PM  
Jun-12-20 10:15AM  
Jun-11-20 08:00AM  
Jun-04-20 11:31AM  
Jun-03-20 04:05PM  
Jun-02-20 02:59AM  
May-28-20 06:58AM  
May-20-20 01:30PM  
May-13-20 05:00PM  
09:54AM  
May-06-20 04:05PM  
11:40AM  
01:01AM  
May-05-20 06:25PM  
04:05PM  
03:00PM  
May-01-20 01:14PM  
Apr-28-20 12:33PM  
Apr-22-20 10:30AM  
09:00AM  
Apr-21-20 04:05PM  
12:59PM  
12:43PM  
Apr-20-20 06:01PM  
04:19PM  
11:03AM  
07:12AM  
06:59AM  
06:59AM  
Apr-09-20 11:40AM  
Apr-08-20 04:05PM  
Mar-26-20 03:41PM  
11:30AM  
Mar-25-20 03:01AM  
Mar-24-20 11:40AM  
Mar-17-20 07:02AM  
Mar-02-20 04:05PM  
Feb-27-20 06:19AM  
12:31AM  
Feb-26-20 04:05PM  
10:03AM  
Feb-25-20 06:35PM  
04:06PM  
04:05PM  
Feb-21-20 11:30AM  
Feb-19-20 07:28AM  
Feb-12-20 04:05PM  
02:10PM  
Feb-11-20 05:50PM  
07:23AM  
Feb-10-20 05:00PM  
Feb-04-20 05:50PM  
Jan-29-20 08:30AM  
02:01AM  
Jan-28-20 09:52AM  
Jan-27-20 08:07AM  
Jan-24-20 07:30AM  
Jan-21-20 06:10PM  
Jan-17-20 11:40AM  
Jan-14-20 07:38AM  
Jan-13-20 12:10PM  
Jan-12-20 04:00PM  
Jan-09-20 04:39PM  
Jan-08-20 10:13AM  
10:07AM  
Jan-07-20 04:05PM  
07:30AM  
Dec-19-19 07:00AM  
Dec-13-19 08:22AM  
08:10AM  
01:02AM  
Dec-06-19 01:03PM  
Dec-05-19 04:56AM  
Nov-26-19 04:06PM  
12:20PM  
Nov-12-19 04:05PM  
08:02AM  
Nov-07-19 08:01PM  
Nov-05-19 03:36AM  
Oct-31-19 11:45AM  
Oct-30-19 06:45PM  
04:05PM  
08:00AM  
Oct-29-19 10:40AM  
Oct-25-19 10:15AM  
Oct-23-19 10:33AM  
Oct-16-19 04:05PM  
Oct-14-19 12:08PM  
Oct-07-19 11:58AM  
09:54AM  
Oct-01-19 11:45AM  
Sep-25-19 04:05PM  
Sep-23-19 10:27AM  
Sep-20-19 05:48PM  
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, Exelixis, Inc. is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, and other kinases implicated in growth and spread of cancer. It has collaboration and license agreement with Ipsen Pharma SAS, Takeda Pharmaceutical Company Ltd., Roche, Aurigene Discovery Technologies Limited, Iconic Therapeutics, Inc., Invenra, Inc., StemSynergy Therapeutics, Inc., Genentech, Inc., GlaxoSmithKline, Bristol-Myers Squibb Company, Merck, and Daiichi Sankyo Company, Limited. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in Alameda, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MORRISSEY MICHAELPresident and CEOJun 19Option Exercise6.21100,000621,000185,985Jun 19 09:20 PM
Lamb PeterEVP, Scientific Strategy & CSOJun 08Option Exercise5.5126,000143,260152,531Jun 10 08:19 PM
Lamb PeterEVP, Scientific Strategy & CSOJun 08Sale22.5626,000586,560126,531Jun 10 08:19 PM
Schwab GiselaPres, Prod Dev & Med Aff & CMOJun 04Option Exercise1.70100,000170,000425,963Jun 05 08:00 PM
Schwab GiselaPres, Prod Dev & Med Aff & CMOJun 04Sale22.96100,0002,296,000325,963Jun 05 08:00 PM
MORRISSEY MICHAELPresident and CEOMay 29Option Exercise6.21100,000621,000185,985May 29 09:36 PM
Garber Alan MDirectorMay 22Sale24.4236,111881,83112,718May 22 08:53 PM
MARCHESI VINCENT TDirectorMay 21Option Exercise5.8240,000232,800130,212May 22 09:11 PM
MARCHESI VINCENT TDirectorMay 21Sale24.6440,000985,60090,212May 22 09:11 PM
Haley Patrick J.EVP, CommercialMay 20Sale24.993,15178,743115,340May 22 08:17 PM
WILLSEY LANCEDirectorMay 18Option Exercise4.5830,000137,400398,273May 20 08:36 PM
SCANGOS GEORGE ADirectorMay 18Sale25.9675,0001,947,000714,717May 20 08:35 PM
WILLSEY LANCEDirectorMay 18Sale26.2630,000787,800368,273May 20 08:36 PM
MORRISSEY MICHAELPresident and CEOMay 15Option Exercise6.21100,000621,000185,985May 15 09:29 PM
SCANGOS GEORGE ADirectorMay 15Option Exercise5.1051,686263,613789,717May 15 08:31 PM
WILLSEY LANCEDirectorMay 14Option Exercise5.9215,00088,800383,273May 15 08:19 PM
WILLSEY LANCEDirectorMay 14Sale25.2615,000378,900368,273May 15 08:19 PM
PAPADOPOULOS STELIOSDirectorMay 13Option Exercise5.82120,791703,0041,173,359May 15 08:18 PM
Hessekiel JeffreyEVP and General CounselMay 13Option Exercise1.7025,00042,500264,188May 15 08:20 PM
Hessekiel JeffreyEVP and General CounselMay 11Option Exercise1.9038,00672,211277,194May 11 08:36 PM
MARCHESI VINCENT TDirectorMay 11Option Exercise4.5830,000137,400112,484May 13 09:16 PM
Hessekiel JeffreyEVP and General CounselMay 11Sale27.0938,0061,029,583239,188May 11 08:36 PM
MARCHESI VINCENT TDirectorMay 11Sale26.3030,000789,00082,484May 13 09:16 PM
Haley Patrick J.EVP, CommercialMay 08Option Exercise1.7621,37537,620139,866May 08 09:16 PM
PAPADOPOULOS STELIOSDirectorMay 08Option Exercise5.0345,000226,2001,097,568May 08 09:18 PM
Senner Christopher J.EVP and CFOMay 08Option Exercise3.6678,583287,614199,286May 08 09:22 PM
Hessekiel JeffreyEVP and General CounselMay 08Option Exercise1.9025,00047,500264,188May 11 08:36 PM
Haley Patrick J.EVP, CommercialMay 08Sale25.8721,375552,971118,491May 08 09:16 PM
PAPADOPOULOS STELIOSDirectorMay 08Sale25.8445,0001,162,8001,052,568May 08 09:18 PM
Senner Christopher J.EVP and CFOMay 08Sale25.8178,5832,028,227120,703May 08 09:22 PM
Hessekiel JeffreyEVP and General CounselMay 08Sale26.0425,000651,000239,188May 11 08:36 PM
Lamb PeterEVP, Scientific Strategy & CSOMay 07Option Exercise5.5150,000275,500176,531May 08 09:11 PM
POSTE GEORGEDirectorMay 07Option Exercise5.8230,000174,600142,792May 08 09:13 PM
FELDBAUM CARL BDirectorMay 07Option Exercise4.2731,546134,79840,067May 08 09:14 PM
Senner Christopher J.EVP and CFOMay 07Option Exercise3.6621,41778,386142,120May 08 09:22 PM
Hessekiel JeffreyEVP and General CounselMay 07Option Exercise1.9030,00057,000269,188May 11 08:36 PM
FELDBAUM CARL BDirectorMay 07Sale25.0231,546789,2818,521May 08 09:14 PM
POSTE GEORGEDirectorMay 07Sale25.6130,000768,300112,792May 08 09:13 PM
Senner Christopher J.EVP and CFOMay 07Sale25.8021,417552,559120,703May 08 09:22 PM
Lamb PeterEVP, Scientific Strategy & CSOMay 07Sale25.5450,0001,277,000126,531May 08 09:11 PM
Hessekiel JeffreyEVP and General CounselMay 07Sale25.6130,000768,300239,188May 11 08:36 PM
MORRISSEY MICHAELPresident and CEOMay 06Option Exercise1.70285,284484,983371,269May 08 09:10 PM
MORRISSEY MICHAELPresident and CEOApr 27Option Exercise1.70285,000484,500370,985Apr 29 08:10 PM
SCANGOS GEORGE ADirectorApr 24Sale26.2415,000393,600738,031Apr 24 08:24 PM
Haley Patrick J.EVP, CommercialApr 23Option Exercise1.705,0008,500121,873Apr 24 08:22 PM
MORRISSEY MICHAELPresident and CEOApr 23Option Exercise5.51250,0001,377,500335,985Apr 24 08:41 PM
Schwab GiselaPres, Prod Dev & Med Aff & CMOApr 23Option Exercise1.70100,000170,000425,122Apr 24 08:25 PM
SCANGOS GEORGE ADirectorApr 23Sale25.99100,0002,598,635753,031Apr 24 08:24 PM
Haley Patrick J.EVP, CommercialApr 23Sale26.005,000130,000116,873Apr 24 08:22 PM
Schwab GiselaPres, Prod Dev & Med Aff & CMOApr 23Sale26.00100,0002,600,000325,122Apr 24 08:25 PM
SCANGOS GEORGE ADirectorApr 22Sale25.054,200105,210853,031Apr 22 08:50 PM
MORRISSEY MICHAELPresident and CEOApr 21Option Exercise5.51220,0001,212,200393,064Apr 22 09:53 PM
SCANGOS GEORGE ADirectorApr 21Sale25.045,800145,232857,231Apr 22 08:50 PM
Haley Patrick J.EVP, CommercialApr 20Option Exercise1.705,0008,500121,873Apr 22 08:49 PM
MORRISSEY MICHAELPresident and CEOApr 20Option Exercise5.51240,0001,322,400325,985Apr 22 09:53 PM
SCANGOS GEORGE ADirectorApr 20Sale23.8950,0001,194,637863,031Apr 22 08:50 PM
Haley Patrick J.EVP, CommercialApr 20Sale24.005,000120,000116,873Apr 22 08:49 PM
SCANGOS GEORGE ADirectorApr 15Sale18.3125,000457,750913,031Apr 17 08:11 PM
SCANGOS GEORGE ADirectorApr 08Sale18.357,065129,643938,031Apr 09 08:20 PM
SCANGOS GEORGE ADirectorApr 07Sale18.2516,435299,939945,096Apr 09 08:20 PM
Lamb PeterEVP, Scientific Strategy & CSOApr 06Option Exercise5.5150,000275,500176,531Apr 08 08:12 PM
Lamb PeterEVP, Scientific Strategy & CSOApr 06Sale17.2650,000863,000126,531Apr 08 08:12 PM
WYSZOMIERSKI JACK LDirectorApr 03Option Exercise5.0345,000226,200175,526Apr 03 08:38 PM
WYSZOMIERSKI JACK LDirectorApr 03Sale16.5713,848229,461161,678Apr 03 08:38 PM
SCANGOS GEORGE ADirectorMar 31Sale18.061,50027,090961,531Apr 02 08:08 PM
Haley Patrick J.EVP, CommercialMar 20Sale15.374,31866,368116,873Mar 20 09:03 PM
Schwab GiselaPres, Prod Dev & Med Aff & CMOMar 04Option Exercise1.70100,000170,000425,122Mar 06 08:01 PM
MORRISSEY MICHAELPresident and CEOMar 04Option Exercise5.5150,000275,500135,985Mar 06 08:07 PM
Schwab GiselaPres, Prod Dev & Med Aff & CMOMar 04Sale19.40100,0001,940,000325,122Mar 06 08:01 PM
FELDBAUM CARL BDirectorMar 03Option Exercise5.6238,000213,72046,521Mar 05 08:00 PM
FELDBAUM CARL BDirectorMar 03Sale18.8438,000716,0138,521Mar 05 08:00 PM
COHEN CHARLESDirectorFeb 28Option Exercise5.0345,000226,20065,979Mar 02 09:14 PM
MORRISSEY MICHAELPresident and CEOFeb 26Option Exercise5.5125,000137,750110,985Feb 28 08:05 PM
MORRISSEY MICHAELPresident and CEOFeb 26Sale18.9125,000472,85085,985Feb 28 08:05 PM
Schwab GiselaPres, Prod Dev & Med Aff & CMOFeb 19Option Exercise5.5140,000220,400365,122Feb 21 08:00 PM
MORRISSEY MICHAELPresident and CEOFeb 19Option Exercise0.0025,0000110,985Feb 21 08:03 PM
Haley Patrick J.EVP, CommercialFeb 19Option Exercise0.005,0000126,191Feb 21 08:17 PM
Haley Patrick J.EVP, CommercialFeb 19Sale22.005,000110,000121,191Feb 21 08:17 PM
MORRISSEY MICHAELPresident and CEOFeb 19Sale21.7525,000543,75085,985Feb 21 08:03 PM
Schwab GiselaPres, Prod Dev & Med Aff & CMOFeb 19Sale21.5040,000860,000325,122Feb 21 08:00 PM
SCANGOS GEORGE ADirectorFeb 18Sale20.7350,0001,036,500963,031Feb 21 08:28 PM
Garber Alan MDirectorFeb 14Sale21.0212,500262,75048,829Feb 14 08:36 PM
MORRISSEY MICHAELPresident and CEOFeb 13Option Exercise5.5125,000137,750110,985Feb 14 08:48 PM
MORRISSEY MICHAELPresident and CEOFeb 13Sale20.1125,000502,75085,985Feb 14 08:48 PM
SCANGOS GEORGE ADirectorFeb 12Sale20.0221,000420,4201,013,031Feb 12 08:21 PM
SCANGOS GEORGE ADirectorFeb 11Sale20.144,00080,5601,034,031Feb 12 08:21 PM
Schwab GiselaPres, Prod Dev & Med Aff & CMOFeb 07Option Exercise5.5150,000275,500375,122Feb 07 08:43 PM
Schwab GiselaPres, Prod Dev & Med Aff & CMOFeb 07Sale18.3750,000918,500325,122Feb 07 08:43 PM
MORRISSEY MICHAELPresident and CEOJan 29Option Exercise5.5125,000137,750110,985Jan 31 08:03 PM
MORRISSEY MICHAELPresident and CEOJan 29Sale17.8725,000446,75085,985Jan 31 08:03 PM
MORRISSEY MICHAELPresident and CEOJan 23Option Exercise5.5125,000137,750110,985Jan 24 08:19 PM
MORRISSEY MICHAELPresident and CEOJan 23Sale19.4125,000485,25085,985Jan 24 08:19 PM
SCANGOS GEORGE ADirectorJan 22Sale19.7525,000493,7501,038,031Jan 24 08:17 PM
MORRISSEY MICHAELPresident and CEOJan 16Option Exercise5.5125,000137,750110,985Jan 17 08:45 PM
MORRISSEY MICHAELPresident and CEOJan 16Sale20.3325,000508,25085,985Jan 17 08:45 PM
MARCHESI VINCENT TDirectorJan 15Sale20.0161,6831,234,27782,484Jan 17 08:50 PM
SCANGOS GEORGE ADirectorJan 15Sale20.3925,000509,7501,063,031Jan 17 08:42 PM
MORRISSEY MICHAELPresident and CEOJan 08Option Exercise5.5125,000137,750110,985Jan 09 08:35 PM
MORRISSEY MICHAELPresident and CEOJan 08Sale18.8525,000471,25085,985Jan 09 08:35 PM
Schwab GiselaPres, Prod Dev & Med Aff & CMOJan 07Option Exercise5.5150,000275,500375,122Jan 09 08:27 PM